LONDON (Reuters) – GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process.
Potential bidders include private equity firm KKR, India’s Lupin and Denmark’s Lundbeck, all of which are interested in acquiring rights to products in certain regions.
LONDON (Reuters) – AstraZeneca’s cancer drug pipeline, already on a roll following promising clinical trial results, could get a further boost next week from a European green light for an experimental medicine against ovarian cancer.
European Medicines Agency experts will consider whether to recommend approval of olaparib at their regular monthly meeting, with a decision expected on Oct. 23 or 24, a company spokeswoman said.
LONDON (Reuters) – The reliability of clinical tests used to win approval for some medicines — particularly generic copies of original drugs — could be in doubt due to an apparent software glitch that may mean data was calculated incorrectly.
An official at the London-based European Medicines Agency (EMA) told Reuters that the issue, involving Thermo Fisher Scientific’s Kinetica package, would be discussed by European regulators at a meeting next week.
LONDON, Oct 13 (Reuters) – A novel spray-on skin treatment
consisting of living cells made by Smith & Nephew, which
is designed to work with the body’s own cells to help heal leg
ulcers, has failed in a late-stage clinical trial.
The product, known as HP802-247, was viewed by some analysts
as a key pipeline asset in the company’s advanced wound
management division and the Phase III failure is a setback for
the healthcare group, which is a regular subject of takeover